Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1

Hensley PJ, Seiler R, Herr H, Mouw KW, Iyer G, Dyrskjøt L, Nawroth R, Goebell P, Schmitz B, Todenhofer T, Black PC, Kamat AM, Williams SB (2023)

Publication Type: Journal article, Review article

Publication year: 2023

Journal

Urologic Oncology-Seminars and Original Investigations Elsevier

DOI: 10.1016/j.urolonc.2023.01.001

Abstract

The morbidity associated with radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) has fueled investigations into the feasibility of bladder preservation strategies after a favorable clinical response to neoadjuvant therapy (NAT). Identifying optimal candidates for bladder preservation is predicated on our ability to identify tumors with inherent cisplatin sensitivity and accurately stage patients before and after NAT. In the present review, we evaluate the accuracy and limitations of contemporary staging modalities and investigate clinical outcomes in patients with MIBC who were managed with bladder preservation after NAT. Lastly, we discuss the predictive role of cisplatin-sensitizing DNA damage response (DDR) gene alterations as a foundational component to current prospective clinical trials evaluating bladder preservation in the setting of MIBC.

Authors with CRIS profile

Peter Goebell Urologische Klinik Bernd Schmitz Medizinische Fakultät

Involved external institutions

Memorial Sloan Kettering Cancer Center US United States (USA) (US) University of Kentucky US United States (USA) (US) Universität Bern CH Switzerland (CH) Klinikum rechts der Isar DE Germany (DE) Aarhus University DK Denmark (DK) University of Texas MD Anderson Cancer Center US United States (USA) (US) University of British Columbia CA Canada (CA) University of Texas Medical Branch (UTMB) US United States (USA) (US) Universitätsklinikum Tübingen DE Germany (DE) Veterans Affairs Healthcare System Boston and Harvard Medical School US United States (USA) (US)

How to cite

APA:

Hensley, P.J., Seiler, R., Herr, H., Mouw, K.W., Iyer, G., Dyrskjøt, L.,... Williams, S.B. (2023). Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1. Urologic Oncology-Seminars and Original Investigations. https://dx.doi.org/10.1016/j.urolonc.2023.01.001

MLA:

Hensley, Patrick J., et al. "Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1." Urologic Oncology-Seminars and Original Investigations (2023).

BibTeX: Download